Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics Assays
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute (NCI) has launched an Assay Portal (http://assays.cancer.gov) to serve as an open-source repository of well-characterized targeted proteomic assays. The portal is designed to curate and disseminate highly characterized, targeted mass spectrometry (MS)-based assays by providing detailed assay performance characterization data, standard operating procedures, and access to reagents. Assay content is accessed via the portal through queries to find assays targeting proteins associated with specific cellular pathways, protein complexes, or specific chromosomal regions. The position of the peptide analytes for which there are available assays are mapped relative to other features of interest in the protein, such as sequence domains, isoforms, single nucleotide polymorphisms, and posttranslational modifications. The overarching goals are to enable robust quantification of all human proteins and to standardize the quantification of targeted MS-based assays to ultimately enable harmonization of results over time and across laboratories.
Key wordsMultiple reaction monitoring Selected reaction monitoring MRM SRM PRM Quantitative proteomics Targeted mass spectrometry Quantitative assay database Harmonization Standardization
This work was funded by the Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the US National Cancer Institute (U24CA160034, U24CA160036, U24CA160019, U24CA159988, and U24CA160035), R01 GM103551, and U01 CA164186.
- 11.Hornbeck PV, Kornhauser JM, Tkachev S et al (2012) PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res 40:D261–D270. doi: 10.1093/nar/gkr1122 PubMedCentralCrossRefPubMedGoogle Scholar